275 related articles for article (PubMed ID: 30952488)
1. Stroke Recurrence in Nigerian Children With Sickle Cell Disease: Evidence for a Secondary Stroke Prevention Trial.
Abdullahi SU; DeBaun MR; Jordan LC; Rodeghier M; Galadanci NA
Pediatr Neurol; 2019 Jun; 95():73-78. PubMed ID: 30952488
[TBL] [Abstract][Full Text] [Related]
2. Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial).
Galadanci NA; Umar Abdullahi S; Vance LD; Musa Tabari A; Ali S; Belonwu R; Salihu A; Amal Galadanci A; Wudil Jibir B; Bello-Manga H; Neville K; Kirkham FJ; Shyr Y; Phillips S; Covert BV; Kassim AA; Jordan LC; Aliyu MH; DeBaun MR
Am J Hematol; 2017 Aug; 92(8):780-788. PubMed ID: 28439953
[TBL] [Abstract][Full Text] [Related]
3. Primary stroke prevention in Nigerian children with sickle cell disease (SPIN): challenges of conducting a feasibility trial.
Galadanci NA; Abdullahi SU; Tabari MA; Abubakar S; Belonwu R; Salihu A; Neville K; Kirkham F; Inusa B; Shyr Y; Phillips S; Kassim AA; Jordan LC; Aliyu MH; Covert BV; DeBaun MR
Pediatr Blood Cancer; 2015 Mar; 62(3):395-401. PubMed ID: 25399822
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial.
Abdullahi SU; Jibir BW; Bello-Manga H; Gambo S; Inuwa H; Tijjani AG; Idris N; Galadanci A; Hikima MS; Galadanci N; Borodo A; Tabari AM; Haliru L; Suleiman A; Ibrahim J; Greene BC; Ghafuri DL; Rodeghier M; Slaughter JC; Kirkham FJ; Neville K; Kassim A; Trevathan E; Jordan LC; Aliyu MH; DeBaun MR
Lancet Haematol; 2022 Jan; 9(1):e26-e37. PubMed ID: 34971579
[TBL] [Abstract][Full Text] [Related]
5. Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial.
Abdullahi SU; Sunusi S; Abba MS; Sani S; Inuwa HA; Gambo S; Gambo A; Musa B; Covert Greene BV; Kassim AA; Rodeghier M; Hussaini N; Ciobanu M; Aliyu MH; Jordan LC; DeBaun MR
Blood; 2023 Feb; 141(8):825-834. PubMed ID: 36322937
[TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience.
Gulbis B; Haberman D; Dufour D; Christophe C; Vermylen C; Kagambega F; Corazza F; Devalck C; Dresse MF; Hunninck K; Klein A; Le PQ; Loop M; Maes P; Philippet P; Sariban E; Van Geet C; Ferster A
Blood; 2005 Apr; 105(7):2685-90. PubMed ID: 15604217
[TBL] [Abstract][Full Text] [Related]
7. Annual stroke incidence in Nigerian children with sickle cell disease and elevated TCD velocities treated with hydroxyurea.
Lagunju I; Brown BJ; Oyinlade AO; Asinobi A; Ibeh J; Esione A; Sodeinde OO
Pediatr Blood Cancer; 2019 Mar; 66(3):e27252. PubMed ID: 29797633
[TBL] [Abstract][Full Text] [Related]
8. Establishing Sickle Cell Disease Stroke Prevention Teams in Africa is Feasible: Program Evaluation Using the RE-AIM Framework.
Ghafuri DL; Abdullahi SU; Dambatta AH; Galadanci J; Tabari MA; Bello-Manga H; Idris N; Inuwa H; Tijjani A; Suleiman AA; Jibir BW; Gambo S; Gambo AI; Khalifa Y; Haliru L; Abdulrasheed S; Zakari MA; Greene BC; Trevathan E; Jordan LC; Aliyu MH; Baumann AA; DeBaun MR
J Pediatr Hematol Oncol; 2022 Jan; 44(1):e56-e61. PubMed ID: 34001783
[TBL] [Abstract][Full Text] [Related]
9. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy.
Ware RE; Zimmerman SA; Sylvestre PB; Mortier NA; Davis JS; Treem WR; Schultz WH
J Pediatr; 2004 Sep; 145(3):346-52. PubMed ID: 15343189
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
Tshilolo L; Tomlinson G; Williams TN; Santos B; Olupot-Olupot P; Lane A; Aygun B; Stuber SE; Latham TS; McGann PT; Ware RE;
N Engl J Med; 2019 Jan; 380(2):121-131. PubMed ID: 30501550
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial.
Aygun B; Lane A; Smart LR; Santos B; Tshilolo L; Williams TN; Olupot-Olupot P; Stuber SE; Tomlinson G; Latham T; Ware RE;
Lancet Haematol; 2024 Jun; 11(6):e425-e435. PubMed ID: 38701812
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial.
Ambrose EE; Latham TS; Songoro P; Charles M; Lane AC; Stuber SE; Makubi AN; Ware RE; Smart LR
Lancet Haematol; 2023 Apr; 10(4):e261-e271. PubMed ID: 36870358
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and Safety of Hydroxyurea in the Treatment of Sickle Cell Anaemia Children in Jos, North Central Nigeria.
Ofakunrin AOD; Oguche S; Adekola K; Okpe ES; Afolaranmi TO; Diaku-Akinwumi IN; Zoakah AI; Sagay AS
J Trop Pediatr; 2020 Jun; 66(3):290-298. PubMed ID: 31608959
[TBL] [Abstract][Full Text] [Related]
14. Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload.
Greenway A; Ware RE; Thornburg CD
Am J Hematol; 2011 Apr; 86(4):357-61. PubMed ID: 21442640
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
John CC; Opoka RO; Latham TS; Hume HA; Nabaggala C; Kasirye P; Ndugwa CM; Lane A; Ware RE
N Engl J Med; 2020 Jun; 382(26):2524-2533. PubMed ID: 32579813
[TBL] [Abstract][Full Text] [Related]
16. Approximately 40 000 children with sickle cell anemia require screening with TCD and treating with hydroxyurea for stroke prevention in three states in northern Nigeria.
Galadanci AA; Galadanci NA; Jibir BW; Abdullahi SU; Idris N; Gambo S; Ali Abubakar SA; Kabo NA; Bello-Manga H; Haliru L; Bashir I; Aliyu MH; Galadanci JA; DeBaun MR
Am J Hematol; 2019 Nov; 94(11):E305-E307. PubMed ID: 31423630
[No Abstract] [Full Text] [Related]
17. Transcranial Doppler screening in Nigerian children with sickle cell disease: A 10-year longitudinal study on the SPPIBA cohort.
Lagunju IA; Labaeka A; Ibeh JN; Orimadegun AE; Brown BJ; Sodeinde OO
Pediatr Blood Cancer; 2021 Apr; 68(4):e28906. PubMed ID: 33522690
[TBL] [Abstract][Full Text] [Related]
18. Stroke recurrence in Nigerian children with sickle cell disease treated with hydroxyurea.
Lagunju IA; Brown BJ; Sodeinde OO
Niger Postgrad Med J; 2013 Sep; 20(3):181-7. PubMed ID: 24287747
[TBL] [Abstract][Full Text] [Related]
19. Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial.
Galadanci NA; Abdullahi SU; Ali Abubakar S; Wudil Jibir B; Aminu H; Tijjani A; Abba MS; Tabari MA; Galadanci A; Borodo AM; Belonwu R; Salihu AS; Rodeghier M; Ghafuri DL; Covert C Greene BV; Neville K; Kassim AA; Kirkham FJ; Jordan LC; Aliyu MH; DeBaun MR
Am J Hematol; 2020 Sep; 95(9):E247-E250. PubMed ID: 32510680
[No Abstract] [Full Text] [Related]
20. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children.
Strouse JJ; Lanzkron S; Beach MC; Haywood C; Park H; Witkop C; Wilson RF; Bass EB; Segal JB
Pediatrics; 2008 Dec; 122(6):1332-42. PubMed ID: 19047254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]